In continuing coverage, Bloomberg News 
(4/20) reported, "Novo Nordisk A/S (NOVOB) said it rejects assertions
by the US group Public Citizen that the diabetes drug Victoza
[liraglutide] should be pulled from the market." This action comes in
wake of Public Citizen's announcement on Thursday that "the drug puts
patients at higher risk of thyroid cancer, pancreatitis and other
problems."
(4/20) reported, "Novo Nordisk A/S (NOVOB) said it rejects assertions
by the US group Public Citizen that the diabetes drug Victoza
[liraglutide] should be pulled from the market." This action comes in
wake of Public Citizen's announcement on Thursday that "the drug puts
patients at higher risk of thyroid cancer, pancreatitis and other
problems."
Currently, labeling on the drug "warns patients and doctors that Victoza
caused thyroid tumors and cancer in animal studies involving rats and
mice," WebMD
(4/21, McMillen) reported. The Food and Drug Administration has
"declined to comment. A representative of the agency said the FDA would
respond directly to Public Citizen after reviewing the petition."
(4/21, McMillen) reported. The Food and Drug Administration has
"declined to comment. A representative of the agency said the FDA would
respond directly to Public Citizen after reviewing the petition."
No comments:
Post a Comment